Counting the cost of caplacizumab

摘要

In this issue of Blood, Goshua et al present a timely cost-effectiveness analysis of caplacizumab for immune thrombotic thrombocytopenic purpura (iTTP) and conclude that adding caplacizumab to standard-of-care (SOC) therapy with plasma exchange and immunosuppression is not cost-effective based on outcomes including duration of hospitalization and iTTP recurrence.(1)